AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 14 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer -- Inoculating solid tumors with genetic material is a promising concept with a common stumbling block - delivery to the targeted cells.
Now researchers may have found a solution using a modified version of the herpes simplex virus as a carrier for murine B7-1.
"Although the B7 family is known to be the most potent of the co-stimulatory molecules, gene transduction of B7 alone has not been effective in inducing anti-tumor immunity in nonimmunogenic tumors by ex vivo methods, much less in vivo," wrote T. Todo and colleagues in Cancer Research.
The researchers used defective herpes simplex virus vectors with resistance to oncolytic replication to carry soluble B7-1 genetic material to the tumor site in mouse models.
Tumor cells of the mouse neuroblastoma Neuro2a were able to incorporate the genetic material successfully, and their growth was inhibited ("In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity," Cancer Res, 2001;61(1):153-161).
Though low titers were used, and B7-1 was observable in only 1% of inoculated cells, mice with intracerebral tumors survived longer compared to controls, and ...
Source: HighBeam Research, Herpes Simplex Virus Delivers Vaccine To Tumor Cells.